|MDACC Study No:||2007-0685 (clinicaltrials.gov NCT No: NCT00948064)|
|Title:||A Phase 2 Trial of Vorinostat in Combination with Azacitidine in Patients with Newly-Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome who are ineligible for other Leukemia Protocols|
|Principal Investigator:||Guillermo Garcia-Manero|
|Treatment Agent:||Azacitidine; Vorinostat|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
azacitidine and vorinostat can help to control AML or MDS better than
azacitidine alone. The safety of this drug combination will also be studied.